Keith Hanigan, Vice President Oncology Marketing at Natera, shared a post on LinkedIn:
“So many highlights from Natera at ASCO GI this weekend, including a successful readout of the 80702 trial in colorectal cancer.
Of note, Signatera-positive patients treated with both adjuvant chemotherapy and celecoxib showed a 40% improvement in overall survival versus chemotherapy alone. This marks an unprecedented moment in personalized medicine for patients with colorectal cancer.
Thank you to all involved in this first-of-its-kind study.”
